Q-omics provides the consensus-scored FFAR4 profile across patient tissues and cancer cell-line models. FFAR4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FFAR4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FFAR4 RNA expression shows 16,589 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where FFAR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FFAR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FFAR4 survival associations across molecular data types. FFAR4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FFAR4 RNA expression–survival associations across cancer types. High FFAR4 expression shows unfavorable associations in LGG, SCLC and STAD, but favorable associations in SKCM, HNSC and DLBC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FFAR4 RNA expression.
This table summarizes FFAR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FFAR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FFAR4 shows lower tumor expression in LUSC, LUAD and BRCA and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher FFAR4 RNA expression in tumor versus normal tissue (log2 FC = +1.232, t-test p < 0.001).
This table shows molecular features associated with FFAR4 in patient tissues and cancer cell lines. In patient samples, FFAR4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FFAR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
